ACE2 News and Research

RSS

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

Researchers investigated the potency of trimeric human nephrocystin SH3, TriSb92, a domain-derived antibody, against a conserved region in the receptor-binding domain (RBD) of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

31 Dec 2021

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

An integrated computational methodology for COVID drug prioritization

Researchers recently published a study in the journal Briefings in Bioinformatics wherein they integrated multiple bioinformatics and cheminformatics-based methods to prioritize drugs for the treatment of COVID-19.

29 Dec 2021

Omicron analysis shows no clear evidence for increased virulence or lethality

Researchers conducted a genomic sequencing and epidemiological correlation analysis of the SARS-CoV-2 Omicron variant.

29 Dec 2021

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

Animal study suggests Omicron is less infectious than previous SARS-CoV-2 strains

A new study suggests the Omicron (B.1.1.529) variant is not as infectious as scientists initially assumed.

29 Dec 2021

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Now in new research, scientists from the University of Leicester have been investigating how these mutations alter the affinities of RBDs to ACE2.

28 Dec 2021

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Researchers from the University of Colorado Anschutz Medical Campus have been investigating the changes imparted on the Gamma variant by three RBD mutations.

28 Dec 2021

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

28 Dec 2021

ACE2 News and Research

The impact of natural selection on sequence diversity in SARS-CoV-2

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

How much do mutations reduce vaccine effectiveness in the Omicron variant?

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

An integrated computational methodology for COVID drug prioritization

Omicron analysis shows no clear evidence for increased virulence or lethality

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Animal study suggests Omicron is less infectious than previous SARS-CoV-2 strains

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

Researchers discover antibodies that neutralize omicron and other SARS-CoV-2 variants

SARS-CoV-2 spreads through cell-to-cell transmission, study finds

Cryo-EM of Omicron variant reveals antibody evasion by spike-ACE2 complex

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News